AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06157996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tislelizumab plus CapeOX chemotherapy
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
Study NCT05525052 — intervention group
Intervention type: OTHER
Intervention: Trans-Facet fixation
Description: Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
Study NCT00236990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentosan polysulfate sodium
Study NCT04316611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Description: Direct intravenous injection (IVD) 20 mmol potassium chloride
Study NCT06157541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic cytomegalovirus-specific T cells
Description: Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
Study NCT06157541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
Study NCT05955924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (500 mg) twice daily
Study NCT05955924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule twice daily
Study NCT05954026 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ExVent
Description: ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
Study NCT06283797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will use Dexcom G6 for continuous glucose monitoring
Study NCT06283797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAID questionnaires
Description: At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
Study NCT06283797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAID questionnaires
Description: At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
Study NCT06003296 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Calcaneocuboid arthrodesis
Description: Calcaneocuboid arthrodesis in triple arthrodesis
Study NCT05549609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XSTEM-VLU
Description: XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
Study NCT05549609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: CryoStor CS10 cryomedium
Study NCT04684095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic patient report outcome
Description: ePRO was conducted every two weeks in addition to routine follow-up
Study NCT06527248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate group
Description: Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
Study NCT06527248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
Study NCT04693325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolonged normothermic machine perfusion
Description: First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
Study NCT05084274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle program
Description: If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
Study NCT05495906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Description: Routine dosing form and dosage
Study NCT05495906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonavalent HPV vaccine
Description: Routine dosing form and dosage
Study NCT05025761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal protection package
Description: The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
Study NCT06008457 — intervention group
Intervention type: DEVICE
Intervention: Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Description: The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB
Description: Inactivated split-virion quadrivalent influenza vaccine
Study NCT04742348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
Study NCT04742348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
Study NCT06307522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Patients will receive subcutaneous administration of MRG-001 at designated visits.
Study NCT03783468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decrease of sedation doses and switch of ventilator settings
Description: tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
Study NCT06311136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valence-Specific Ecological Momentary Intervention
Description: The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
Study NCT04930549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVV-IB
Description: Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVY-IB
Description: Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot A
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot A
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot B
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot B
Study NCT03927131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot C
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot C
Study NCT04930549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo tablets once a day during 12 weeks
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: impedance cardiography
Description: impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: impedance cardiography
Description: impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applanation tonometry
Description: Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Applanation tonometry
Description: Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-ischemic hyperemia of forearm
Description: An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: post-ischemic hyperemia of forearm
Description: An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodynamics parameters
Description: haemodynamics parameters will be evaluated using automatic oscillometric recorder
Study NCT04930549 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: haemodynamics parameters
Description: haemodynamics parameters will be evaluated using automatic oscillometric recorder
Study NCT05460364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1018-1
Description: Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Study NCT05460364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1018-2
Description: Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Study NCT06542601 — intervention group
Intervention type: DEVICE
Intervention: Motor cognitive intervention
Description: Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
Study NCT05407467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin and virgin coconut oil extract (KurCo Smart)
Description: we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
Study NCT05168488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted morning resistance exercise
Description: On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
Study NCT05168488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Afternoon resistance exercise
Description: On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
Study NCT06508658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection
Study NCT06508658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion
Study NCT06508658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule
Study NCT06508658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion
Study NCT06508658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion
Study NCT06560554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented foods
Description: Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
Study NCT06560554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No information on incorporation of fermented foods will be provided for subjects in the control arm.
Study NCT05579626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity statin arm
Description: •high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
Study NCT05579626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity statin plus ezetimibe
Description: •low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
Study NCT05690711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS8179
Description: HRS8179 injection
Study NCT05690711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline
Study NCT04142866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: 2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
Study NCT04142866 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: 2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
Study NCT04142866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-Language Therapy (SLT)
Description: Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
Study NCT05802667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tryptase
Description: Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
Study NCT05744544 — intervention group
Intervention type: PROCEDURE
Intervention: External Oblique Block
Description: Patients will be followed after EOIB which are routinely performed in our clinic.
Study NCT05744544 — intervention group
Intervention type: PROCEDURE
Intervention: m-TAPA block
Description: m-TAPA block
Study NCT04682067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Escalating financial incentives contingent upon biochemical evidence of abstinence
Study NCT04682067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care smoking cessation
Description: Usual care smoking cessation support
Study NCT04682067 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care smoking cessation
Description: Usual care smoking cessation support
Study NCT04142866 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech-Language Therapy (SLT)
Description: Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
Study NCT06287593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA monitoring
Description: Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
Study NCT05891886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
Study NCT05891886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather mask
Description: Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
Study NCT05891886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-rebreather mask
Description: Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
Study NCT06209593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Compleat plant protein tube feed
Description: Patients on a tube feed will act as their own control and switch to new tube feed.
Study NCT05727176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 is an oral FGFR inhibitor
Study NCT06026969 — intervention group
Intervention type: OTHER
Intervention: Neurodevelopmental assessments and follow-up
Description: All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
Study NCT05699993 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Itraconazole was administered orally
Study NCT05699993 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 was administered orally
Study NCT05699993 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan was administered orally
Study NCT04420572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone injection
Description: ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
Study NCT04420572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Description: 1ml betamethasone will be used for steroid injection.
Study NCT05352308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Sense Model Guided Narrative Video
Description: The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
Study NCT06274099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nursing care
Description: It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
Study NCT06274099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing care
Description: It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.